News

24.04.23 Medannex’s First-in-class Therapy Awarded UK ‘Innovation Passport’ to Accelerate Time to Market
01.03.23 MDX-124 receives Orphan Designation from the EMA for the Treatment of Pancreatic Cancer
03.01.23 Medannex features in global pharmaceutical publication ‘Scrip’
12.12.22 Regulators give green light to first-in-human study with MDX-124
08.04.22 Medannex’s first-in-class agent shows significant activity against clinically challenging cancers
21.01.22 Medannex’s monoclonal antibody MDX-124 highly active in pancreatic cancer models
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5